Firategrast 非拉司特; SB 683699|cas:402567-16-2|西域试剂

Firategrast 非拉司特; SB 683699,99.88%

产品编号：Bellancom-14951| CAS NO：402567-16-2| 分子式：C₂₇H₂₇F₂NO₆| 分子量：499.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14951	￥1500.00	杭州北京（现货）
Bellancom-14951	￥2400.00	杭州北京（现货）
Bellancom-14951	￥4900.00	杭州北京（现货）
Bellancom-14951	￥7800.00	杭州北京（现货）
Bellancom-14951	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Firategrast 非拉司特; SB 683699

产品介绍

Firategrast (SB 683699) 是一种具有口服活性的，特异性的 α4β1/α4β7 整联蛋白拮抗剂。 Firategrast 减少淋巴细胞进入中枢神经系统 (CNS) 的运输，降低多发性硬化症 (MS) 的活性。

生物活性

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.

体外研究

Firategrast (0.1-10 µM; 1 hour) significantly reduces chronic lymphocytic leukemia (CLL) cells adhesion.
Firategrast is a potent Integrin α4β1 (VLA-4) antagonist (IC₅₀=198 nM) at inhibiting the binding of soluble VCAM/Fc chimeric protein (sVCAM-1) to G2 acute lymphoblastic leukemia (ALL) cells. VLA-4 is composed of CD49d (α4) and CD29 (β1)^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Firategrast (30 mg/kg/day in drinking water; starting 2 or 7 days post transplantation to 21 days) shows an overall reduction of leukemic cells in the spleen.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Wild-type C57BL/6J mice (8-12 weeks) with primary TCL1-tg splenocytes
Dosage:	30 mg/kg
Administration:	Drinking water; daily; starting 2 or 7 days post transplantation to 21 days
Result:	Showed an overall reduction of leukemic cells in the spleen, accompanied by significant spleen weight reduction.

体内研究

Firategrast (30 mg/kg/day in drinking water; starting 2 or 7 days post transplantation to 21 days) shows an overall reduction of leukemic cells in the spleen.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Wild-type C57BL/6J mice (8-12 weeks) with primary TCL1-tg splenocytes
Dosage:	30 mg/kg
Administration:	Drinking water; daily; starting 2 or 7 days post transplantation to 21 days
Result:	Showed an overall reduction of leukemic cells in the spleen, accompanied by significant spleen weight reduction.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (200.20 mM)

Ethanol : ≥ 50 mg/mL (100.10 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0020 mL	10.0100 mL	20.0200 mL
5 mM	0.4004 mL	2.0020 mL	4.0040 mL
10 mM	0.2002 mL	1.0010 mL	2.0020 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶